# Trends and Hot Spots in Research Related to Rivaroxaban: Bibliometric Analysis

## TL;DR

This study maps research trends on rivaroxaban, identifying new areas of focus like NOAC therapy safety and emerging conditions treated with these drugs.

## Contribution

The novel contribution is identifying new research hot spots in rivaroxaban studies, particularly around NOAC therapy comparisons and safety.

## Key findings

- Research interest in rivaroxaban peaked in 2021 before declining.
- New trends focus on comparing NOAC therapy outcomes with vitamin K antagonists like warfarin.
- Emerging topics include ABCB1, peripheral artery disease, and NOAC use in SARS-CoV-2.

## Abstract

Background: The number of publications related to rivaroxaban is growing, making it difficult for scientists to review relevant materials. Objectives: This bibliometric analysis is focused on highlighting hot spots and new trends associated with rivaroxaban studies and provides references and guidance for further research. Methods: A comparison between countries, journals, authors, and organizations was performed. Microsoft Excel 2021 and VOSviewer were used to process and visualize data extracted from Web of Science. The time range was set from 1991 to late 2024. A total of 6979 articles were analyzed and bibliometric maps of co-citations of references and co-occurrences of the keywords were built. Results: Relative research interest increased until 2021, when it started to drop. The new trends in publications related to rivaroxaban are associated with a comparison of NOAC therapy outcomes with previously used vitamin K antagonists (warfarin). The research was focused also on new NOAC representatives, medical conditions treated with NOAC, and safety of the therapy. New trending topics are related to ABCB1, peripheral artery disease, direct-acting oral anticoagulants, PCI, and SARS-CoV-2. Conclusions: This bibliometric analysis showed that increasing attention is being paid to the medical conditions treated with NOACs and issues related to the safety of this therapy.